The global urinary tract infection testing market was valued at USD 563.0 Million in 2022 and is expected to reach USD 1.1 Billion by 2033. The urinalysis test with around 48.5% in terms of value share, has topped the global market within the testing category in 2022 and is expected to grow at a CAGR of close to 6.0% over the forecast period (2023 to 2033)
Market Outlook:
Data Points | Market Insights |
---|---|
Market Value 2022 | USD 563.0 Million |
Market Value 2023 | USD 593.7 Million |
Market Value 2033 | USD 1.1 Billion |
CAGR 2023 to 2033 | 6.0% |
Market Share of Top 5 Countries | 53.5% |
Key Market Players | ACON Laboratories Inc.; Cardinal Health Inc.; Danaher Corporation; SYSMEX CORPORATION; Abbott Laboratories; Bio-Rad Laboratories; Roche AG; LabCorp(Laboratory Corporation of America Holdings).; Stryker Corporation; Thermo Fisher Scientific, Inc. |
Globally, the number of people suffering from urinary tract infections has increased. Urinary tract infection adds to the world's second-largest patient pool. The market is expected to rise because of rising UTI prevalence and desire for better treatment options. The introduction of innovative testing kits and equipment is likely to propel the urine infection testing industry forward.
With the introduction of new technologies and an increase in the number of urinary tract infection testing kits and device players, the urinary tract infection testing market is likely to expand over the upcoming years.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market for urinary tract infection testing was around 1.6% of the USD 35.0 Billion of the global infectious disease diagnostics market in 2022.
One of the most prevalent bacterial infections, impacting almost 150 million individuals worldwide, is urinary tract infection. Urinary tract infection is most commonly caused by bacteria, viruses, and fungus in the urinary tract. Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Proteus species, and Enterococcus species are few bacteria that cause urinary tract infections.
There is a growing interest in developing creative and effective technology that can quickly and reliably identify UTIs and select the optimum antibiotic to use for a specific patient. This, along with the other factors mentioned, are projected to drive the market in the coming year.
Owed to the above factors, the global market is projected to grow at CAGR of 6.0% in forecasted period.
Recurrence of urinary tract infections is very common, even in uncomplicated cases.
Bacterial persistence occurs when treatment is hampered by the buildup of germs in an area that antibiotics cannot reach, such as infected stones, urethral diverticula, and infected paraurethral glands.
Urinary tract infections are also rather common in males. Prostatitis, pyelonephritis, urethritis, cystitis, epididymitis, orchitis, and infected urinary catheters are all included in the group of adult male UTIs. Due to the numerous defenses the male urinary system has, any such infections are typically linked to anatomical anomalies that frequently call for surgical repair.
The increasing incidence of chronic kidney disease, such as renal failure and bladder cancer, is driving the use of catheters and other drainage devices in patients. Patients with urinary catheters are more likely to contract a complicated UTI. This is expected to boost growth in the UTI testing market over the forecast period.
Bacteria enter the urinary system through improper catheter insertion technique or inadequate cleanliness, resulting in infection. Poor hygiene habits, such as neglecting to clean the catheter or drainage bag, might encourage bacterial development and raise the possibility of UTIs.
Sometimes, catheters can cause urine to build up or stagnate in the bladder, which can foster the growth of germs. Additionally, blockages in the catheter can prevent urine from flowing normally, causing urinary stasis and a higher risk of infection. All of these factors result in a high demand for testing for UTI.
The accuracy of UTI diagnostic tests varies, which might result in false-positive or false-negative results. This can lead to incorrect diagnosis and treatment recommendations. The limitations of existing diagnostic tests may impede their acceptance and limit the growth of the UTI testing market.
The inappropriate and overuse of antibiotics in UTI care can have an impact on the need for UTI testing. Overuse of empirical antibiotic treatment without sufficient diagnostic confirmation can lessen the perceived necessity for diagnostic testing, resulting in UTI test underutilization. Efforts to promote ethical antibiotic usage and evidence-based diagnosis may influence UTI testing demand.
Urine samples are frequently required for UTI diagnostic tests. Obtaining clean-catch urine samples can be difficult, particularly in specific patient populations such as children, the elderly, or those with mobility challenges. Difficulties in collecting samples may have an impact on the accuracy and reliability of UTI tests, limiting their usage.
The USA occupies 31.7% of market share in 2022 globally. UTI is one of the most common bacterial-caused infectious illnesses in the country. A complex urinary tract infection, which is caused by anatomical or functional abnormalities in the urinary system, can afflict anyone, regardless of gender or age.
To avoid complications and achieve optimal patient outcomes, there is a growing emphasis on precise diagnosis and effective therapy of UTIs. As healthcare professionals and patients become more aware of the necessity of diagnostic testing, the demand for UTI tests is increasing.
China expenditure on urinary tract infection testing in 2022 was USD 32.5 Million.
Several policies and programmes have been developed by the Chinese government to enhance healthcare outcomes and minimise healthcare-associated infections, including UTIs.
One key undertaking is the promotion of infection prevention knowledge and education. The goal is to raise awareness among healthcare practitioners and patients about the danger of UTIs and the need of infection prevention.
The government provides healthcare providers with training and instruction to help them improve their knowledge and skills in preventing UTIs. They also concentrate on this effort. Furthermore, encouraging the use of infection prevention measures in healthcare facilities. As a result, China is in high demand in the testing market for urinary tract infections.
In 2022, the Germany held a significant share in the European market and contributed around 23.1% value share in 2022. Germany has a well-developed healthcare system that places a high emphasis on diagnostic services and preventive treatment. The availability of improved healthcare infrastructure, such as diagnostic laboratories and clinics, helps to drive the UTI testing market forward. The rising prevalence of UTIs in the country contributes to the development of the UTI testing market.
UTIs are a widespread health problem in Germany, affecting a large number of people each year. UTIs are becoming more common due to factors such as an ageing population, lifestyle changes, and healthcare-associated illnesses. In Germany, this fuels the demand for UTI testing.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By test, urinalysis held 48.5% market share in world in 2022.
Urinalysis tests are widely used. They are a simple and non-invasive approach for healthcare experts to assess numerous different elements of human health. Urinalysis is frequently used by healthcare providers to screen for or monitor several common health disorders, such as liver disease, kidney disease, and diabetes. These tests' broad applicability are the reason for their significant market share.
The market value of laboratory test kits is representing a sizable 73.3% market share in 2022.
Most laboratories use leukocyte esterase rapid tests to replace microscopic leukocyte counts in urine. A more advanced and exact laboratory investigation of the urine validates the results of these test kits. Because of their precision, these test kits are gaining popularity and assisting in market expansion.
The Cystitis have a considerable presence in the market with market share of 58.6% in 2022. Due to the ageing population, cystitis is the most prevalent type of UTI. Cystitis is frequent in the elderly, especially when they are ill. Bladder catheters and some urinary-tract procedures may further raise the risk of cystitis.
The hospitals have a considerable presence in the urinary tract infection testing market, accounting for 41.7% value share in 2022, and exhibiting a high CAGR of 6.5% over the forecast period. The increased use of laboratory kits in hospitals for UTI detection is resulting in more potent for the UTI treatment, as well as increased patient visits in the hospitals globally each year are aiding the growth of the market.
Collaborations and partnerships among healthcare providers, research institutions, and technology businesses can encourage innovation and hasten urinary tract infection testing. Collaboration in research, development, and commercialization can lead to market expansion and the creation of new applications. Numerous large firms compete in the field of urinary tract infection testing. Among the well-known players in this field are:
Similarly, recent developments related to the companies active in the urinary tract infection testing market have been tracked by the team at Future Market Insights, which are available in the full report.
Attribute | Details |
---|---|
Forecast Period | 2023 to 2033 |
Historical Data Available for | 2017 to 2022 |
Market Analysis | USD Million for Value, Units for Volume |
Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa (MEA) |
Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, China, Japan, South Korea, India, Indonesia, Thailand, Malaysia, Australia, New Zealand, GCC countries, Türkiye, Northern Africa and South Africa. |
Key Market Segments Covered | Test, Test Kits, Indication, End User, and Region |
Key Companies Profiled | ACON Laboratories Inc.; Cardinal Health Inc.; Danaher Corporation; SYSMEX CORPORATION; Abbott Laboratories; Bio-Rad Laboratories; Roche AG; LabCorp (Laboratory Corporation of America Holdings).; Stryker Corporation; Thermo Fisher Scientific, Inc. |
Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
Pricing | Available upon Request |
The overall market was valued at around USD 563 million in 2022 end.
The adoption of urinary tract infection testing services could grow at 6% annually until 2033.
The global market value to cross USD 1,100 million by 2033.
The United States alone had generated nearly 31.7% of the global demand in 2022.
China market accrued nearly USD 32.5 million in 2022.
Explore Healthcare Insights
View Reports